265th ENMC International Workshop: Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands

Mauro Monforte; Shahram Attarian; John Vissing; Jordi Diaz-Manera; Giorgio Tasca; 265th ENMC workshop participants

doi:10.1016/j.nmd.2022.10.005

265th ENMC International Workshop: Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands

Mauro Monforte, Shahram Attarian, John Vissing, Jordi Diaz-Manera, Giorgio Tasca^*, 265th ENMC workshop participants

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Communication

7 Citations (Scopus)

Original language	English
Journal	Neuromuscular Disorders
Volume	33
Issue number	1
Pages (from-to)	65-75
Number of pages	11
ISSN	0960-8966
DOIs	https://doi.org/10.1016/j.nmd.2022.10.005
Publication status	Published - 2023

Keywords

Biomarkers
Facioscapulohumeral Muscular Dystrophy
FSHD
Muscle imaging
Muscle MRI

Access to Document

10.1016/j.nmd.2022.10.005

Cite this

Monforte, M., Attarian, S., Vissing, J., Diaz-Manera, J., Tasca, G., & 265th ENMC workshop participants (2023). 265th ENMC International Workshop: Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands. Neuromuscular Disorders, 33(1), 65-75. https://doi.org/10.1016/j.nmd.2022.10.005

265th ENMC International Workshop : Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands. / Monforte, Mauro; Attarian, Shahram; Vissing, John; Diaz-Manera, Jordi; Tasca, Giorgio; 265th ENMC workshop participants.

In: Neuromuscular Disorders, Vol. 33, No. 1, 2023, p. 65-75.

Research output: Contribution to journal › Journal article › Communication

Monforte, M, Attarian, S, Vissing, J, Diaz-Manera, J, Tasca, G & 265th ENMC workshop participants 2023, '265th ENMC International Workshop: Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands', Neuromuscular Disorders, vol. 33, no. 1, pp. 65-75. https://doi.org/10.1016/j.nmd.2022.10.005

Monforte, Mauro ; Attarian, Shahram ; Vissing, John ; Diaz-Manera, Jordi ; Tasca, Giorgio ; 265th ENMC workshop participants. / 265th ENMC International Workshop : Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands. In: Neuromuscular Disorders. 2023 ; Vol. 33, No. 1. pp. 65-75.

@article{4b5cf68376064ae38fd306c5ad10c7d6,

title = "265th ENMC International Workshop: Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands",

keywords = "Biomarkers, Facioscapulohumeral Muscular Dystrophy, FSHD, Muscle imaging, Muscle MRI",

author = "Mauro Monforte and Shahram Attarian and John Vissing and Jordi Diaz-Manera and Giorgio Tasca and {265th ENMC workshop participants}",

note = "Funding Information: The workshop was made possible thanks to the financial support of the European Neuromuscular center (ENMC) and ENMC main sponsors: Association Fran{\c c}aise contre les Myopathies (France), Deutsche Gesellschaft f{\"u}r Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Fonds (The Netherlands), Schweizerische Stiftung f{\"u}r die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands), and Associated Partners: Finnish Neuromuscular Association (Finland), {\"O}sterreichische Muskelforschung (Austria), SMA Europe and World Duchenne organisation. In addition, we would like to thank the members of the ENMC Company Forum: Sanofi, Roche, Lupin Neuroscience, Amicus Therapeutics, Ionis Pharmaceuticals, Biogen, Novartis, PerkinElmer and Astellas. Funding Information: Data presented by Anna Pichiecchio were generated in a project funded by Italian Ministry of Health (RF-2016–02362914). Funding Information: This workshop was supported by the European Neuromuscular center (ENMC). Funding Information: - Hermien Kan receives research support from Philips Healhtcare and trial support from ImagingDMD. No personal fees are received, all revenues go to the LUMC;",

year = "2023",

doi = "10.1016/j.nmd.2022.10.005",

language = "English",

volume = "33",

pages = "65--75",

journal = "Journal of Neuromuscular Diseases",

issn = "0960-8966",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - 265th ENMC International Workshop

T2 - Muscle imaging in Facioscapulohumeral Muscular Dystrophy (FSHD): relevance for clinical trials. 22–24 April 2022, Hoofddorp, The Netherlands

AU - Monforte, Mauro

AU - Attarian, Shahram

AU - Vissing, John

AU - Diaz-Manera, Jordi

AU - Tasca, Giorgio

AU - 265th ENMC workshop participants

N1 - Funding Information: The workshop was made possible thanks to the financial support of the European Neuromuscular center (ENMC) and ENMC main sponsors: Association Française contre les Myopathies (France), Deutsche Gesellschaft für Muskelkranke (Germany), Muscular Dystrophy Campaign (UK), Muskelsvindfonden (Denmark), Prinses Beatrix Fonds (The Netherlands), Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands), and Associated Partners: Finnish Neuromuscular Association (Finland), Österreichische Muskelforschung (Austria), SMA Europe and World Duchenne organisation. In addition, we would like to thank the members of the ENMC Company Forum: Sanofi, Roche, Lupin Neuroscience, Amicus Therapeutics, Ionis Pharmaceuticals, Biogen, Novartis, PerkinElmer and Astellas. Funding Information: Data presented by Anna Pichiecchio were generated in a project funded by Italian Ministry of Health (RF-2016–02362914). Funding Information: This workshop was supported by the European Neuromuscular center (ENMC). Funding Information: - Hermien Kan receives research support from Philips Healhtcare and trial support from ImagingDMD. No personal fees are received, all revenues go to the LUMC;

PY - 2023

Y1 - 2023

KW - Biomarkers

KW - Facioscapulohumeral Muscular Dystrophy

KW - FSHD

KW - Muscle imaging

KW - Muscle MRI

U2 - 10.1016/j.nmd.2022.10.005

DO - 10.1016/j.nmd.2022.10.005

M3 - Journal article

C2 - 36369218

AN - SCOPUS:85141458374

VL - 33

SP - 65

EP - 75

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

SN - 0960-8966

IS - 1

ER -